Skip to main content

Table 2 Transcripts identified as over-expressed in ERα (+) breast cancers commonly detected by cross-platforms comparison (SAGE and oligonucleotide microarrays).

From: Gene expression signature of estrogen receptor α status in breast cancer

Gene name

Locus Link ID

Fold change

Frequency

Gene name

Locus Link

Fold change

Frequency#

TFF1*

7031

51.4

15/18 (83%)

SULF2

55959

2.9

11/18 (61%)

SYTL4*

94121

28.0

15/18 (83%)

THBS4

7060

2.9

8/18 (44%)

DUSP4

1846

14.7

14/18 (78%)

AZGP1

563

2.8

9/18 (50%)

NAT1

9

11.7

15/18 (83%)

BBC3*

27113

2.8

12/18 (67%)

ECM1*

1893

10.1

13/18 (72%)

NET7*

23555

2.8

10/18 (55%)

KIAA0882

23158

10.1

18/18 (100%)

NET6

27075

2.8

12/18 (67%)

JDP1

56521

10.0

12/18 (67%)

TRAF5

7188

2.8

9/18 (50%)

ESR1

2099

9.8

18/18 (100%)

BTG2

7832

2.7

9/18 (50%)

HDGFRP3

50810

9.8

12/18 (67%)

RNF123*

63891

2.7

11/18 (61%)

TCEAL1

9338

9.8

13/18 (72%)

CHAD*

1101

2.6

12/18 (67%)

TSPAN1*

10103

9.5

15/18 (83%)

CSNK1A1

1452

2.6

14/18 (78%)

C20orf103*

24141

9.3

10/18 (55%)

EVL

51466

2.6

12/18 (67%)

MYLIP

29116

9.3

11/18 (61%)

HIST1H2BD

3017

2.6

10/18 (55%)

ABCA3

21

8.9

10/18 (55%)

SUSD3

203328

2.6

9/18 (50%)

SEC14L2

23541

8.7

9/18 (50%)

PLAT*

5327

2.6

8/18 (44%)

ANXA9*

8416

8.4

10/18 (55%)

RARRES3*

5920

2.6

11/18 (61%)

KCTD3

51133

8.4

17/18 (94%)

SH3BGRL*

6451

2.6

8/18 (44%)

SCUBE2

57758

7.5

14/18 (78%)

TPBG*

7162

2.6

9/18 (50%)

ITGBL1

9358

7.1

8/18 (44%)

UGCG

7357

2.6

11/18 (61%)

C14orf168

83544

6.7

6/18 (33%)

CELSR2*

1952

2.5

8/18 (44%)

FBP1

2203

6.7

14/18 (78%)

CRIM1

51232

2.5

11/18 (61%)

MYB

4602

6.7

14/18 (78%)

FLJ90798*

219654

2.5

9/18 (50%)

RARA*

5914

6.7

12/18 (67%)

KIF12

113220

2.5

7/18 (39%)

CaMKIINα

55450

6.3

18/18 (100%)

LRIG1

26018

2.5

9/18 (50%)

AR*

367

6.2

10/18 (55%)

LRP2*

4036

2.5

10/18 (55%)

ZNF552

79818

6.2

16/18 (89%)

PHF15*

23338

2.5

12/18 (67%)

MIPEP*

4285

6.0

14/18 (78%)

HSMNP1

55861

2.4

8/18 (44%)

BAI2

576

5.3

15/18 (83%)

LOC123169

123169

2.4

12/18 (67%)

DP1L1

92840

5.3

15/18 (83%)

PINK1*

65018

2.4

11/18 (61%)

VAV3

10451

5.3

12/18 (67%)

PRKAR2B

5577

2.4

7/18 (39%)

KIAA0089

23171

5.2

17/18 (94%)

TJP3*

27134

2.4

11/18 (61%)

GATA3

2625

5.1

15/18 (83%)

CCND1

595

2.3

9/18 (50%)

QDPR

5860

5.1

11/18 (61%)

CYBRD1

79901

2.3

10/18 (55%)

C1orf21

81563

4.9

11/18 (61%)

KRT18

3875

2.3

10/18 (55%)

KIAA1143

57456

4.9

7/18 (39%)

PURA

5813

2.3

9/18 (50%)

OIP106

22906

4.9

16/18 (89%)

SREBF1*

6720

2.3

10/18 (55%)

AGR2

10551

4.6

10/18 (55%)

CYB5R1

51706

2.2

6/18 (33%)

MGC4251

84336

4.6

13/18 (72%)

DLG3*

1741

2.2

9/18 (50%)

FER1L3

26509

4.4

10/18 (55%)

EEF1A2

1917

2.2

11/18 (61%)

C4A

720

4.1

11/18 (61%)

GSTZ1

2954

2.2

9/18 (50%)

CRIP2

1397

4.0

15/18 (83%)

LOC159090

159090

2.2

6/18 (33%)

NTN4

59277

4.0

10/18 (55%)

MGC11242*

79170

2.2

10/18 (55%)

GJA1

2697

3.8

11/18 (61%)

MGC18216*

145815

2.2

8/18 (44%)

CGI-111*

51015

3.7

14/18 (78%)

NEIL1

79661

2.2

6/18 (33%)

CROT*

54677

3.6

15/18 (83%)

XBP1*

7494

2.2

8/18 (44%)

DACH

1602

3.6

13/18 (72%)

IRX5

10265

2.1

8/18 (44%)

DKFZP564D172

83989

3.6

10/18 (55%)

RAB31

11031

2.1

9/18 (50%)

FGD3

89846

3.6

10/18 (55%)

SSBP2

23635

2.1

7/18 (39%)

RNASE4*

6038

3.6

12/18 (67%)

TGFB3

7043

2.1

8/18 (44%)

GLUL*

2752

3.3

11/18 (61%)

BMPR1B

658

2.0

7/18 (39%)

FOXA1

3169

3.2

10/18 (55%)

FLJ21174

79921

2.0

6/18 (33%)

MGC7036

196383

3.2

14/18 (78%)

FLJ22386

79641

2.0

7/18 (39%)

MUC1*

4582

3.2

12/18 (67%)

HSPB1*

3315

2.0

6/18 (33%)

NAV1

89796

3.1

13/18 (72%)

IGFBP4*

3487

2.0

8/18 (44%)

RPLP1*

6176

3.1

12/18 (67%)

MGC15737*

85012

2.0

8/18 (44%)

ALCAM

214

2.9

9/18 (50%)

SPARCL1

8404

2.0

9/18 (50%)

HSD17B4*

3295

2.9

13/18 (72%)

STARD10 *

10809

2.0

7/18 (39%)

  1. * Genes with known or putative high-affinity EREs mapping in the vicinity of the TSS.
  2. # Transcripts tags changing > 2-fold when compared with the average expression of ERα (-) tumors. Underlined genes correspond to the transcripts cross-validated among all three compared platforms.